<DOC>
	<DOCNO>NCT02626182</DOCNO>
	<brief_summary>This study evaluate ability drug sildenafil improve exercise capacity , cardiac performance exercise , quality life patient moderate severe CF lung disease . 3/4 subject receive sildenafil 1/4 receive placebo .</brief_summary>
	<brief_title>Evaluation Treatment Pulmonary Vascular Disease Moderate Severe CF</brief_title>
	<detailed_description>Over time , patient Cystic Fibrosis ( CF ) develop disable lung disease progress chronic respiratory failure , exercise intolerance mark limitation physical activity , premature death . Despite substantial improvement care , patient CF often develop pulmonary vascular disease ( PVD ) lead pulmonary hypertension . Previous study clearly link severe pulmonary hypertension right heart failure high mortality CF . Early clinical manifestation PVD prior development cor pulmonale include shortness breath dyspnea exertion , extent PVD contribute decline exercise tolerance quality life patient CF know . Early evidence PVD could recognize CF patient standardize exercise test echocardiographic evaluation . Identifying CF patient PVD prior onset right ventricular dysfunction may allow pharmacologic intervention attenuate progression cardiovascular disease improve quality life . Clinical trial demonstrate treatment phosphodiesterase type 5 inhibitor , sildenafil , decrease pulmonary vascular resistance improve exercise tolerance non-CF patient pulmonary hypertension . Because experimental clinical study implicate impaired NO-cGMP signal pathophysiology lung disease CF , sildenafil may provide novel pharmacological approach treat PVD patient CF lung disease .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Confirmed diagnosis CF base follow criterion : Positive sweat chloride ≥60mEq/liter ( pilocarpine iontophoresis ) and/or Genotype two identifiable mutation consistent CF , accompany one clinical feature consistent CF phenotype 2 . Male female patient ≥ 18 year age 3 . FEV1 ≥ 20 % predict ≤ 70 % predict ( Hankinson ) 4 . Clinically stable without evidence acute upper low respiratory tract infection current pulmonary exacerbation within 14 day prior screen visit 5 . Ability reproducibly perform spirometry ( accord ATS criterion ) 6 . Ability understand sign write informed consent assent comply requirement study 7 . Willingness maintain chronic CF medication schedule ( e.g . alternate month inhale antibiotic ) 1 . History hypersensitivity sildenafil 2 . Use investigational agent within 4week period prior Visit 1 ( Day 0 ) 3 . Breastfeeding , pregnant , verbal expression unwillingness practice acceptable birth control method ( abstinence , hormonal barrier method , partner sterilization intrauterine device ) participation study woman childbearing potential . 4 . History significant hepatic disease ( AST ALT &gt; 5 time upper limit normal screening , document biliary cirrhosis , portal hypertension ) , 5 . History significant cardiovascular disease ( history aortic stenosis , coronary artery disease , lifethreatening arrhythmia ) , 6 . History severe neurological disease ( e.g . history stroke ) , 7 . History severe hematologic disease ( e.g . history bleed diathesis ; current INR &gt; 2.0 8 . History severe ophthalmologic disease ( e.g . history retinal impairment nonarteritic ischemic optic neuritis ) 9 . History severe renal impairment ( creatinine &gt; 1.8 mg/dL . ) 10 . Inability swallow pill 11 . Previous organ transplantation 12 . Use concomitant nitrate , αblocker , Ca channel blocker ( currently within one month Visit 1 ) 13 . Use concomitant medication know potent inhibitor CYP3A4 [ e.g . ketoconazole , itraconazole , ritonavir , clarithromycin , erythromycin , rifampin ( currently within one month initiation study drug ) ] NOTE : use azithromycin NOT cause exclusion 14 . History sputum throat swab culture yield Burkholderia cepacia Mycobacterium massiliense within 2 year screen 15 . Weight le 40 kg Screening 16 . History migraine headache . 17 . Resting room air oxygen saturation &lt; 80 % without supplemental oxygen 18 . Presence condition abnormality opinion investigator would compromise safety subject quality data 19 . Start CFTR modulator therapy le 1 month prior first dose sildenafil placebo 20 . Use anticoagulant 21 . Frank pulmonary hypertension ( RVSP &gt; 40 mmHg ECHO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>